Trial Details
RECRUITINGBasic Information
| Clinical ID | c75 |
|---|---|
| Identifier | NCT07223424 |
| Trial Title | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Renal Cell Carcinoma|Non Small Cell Lung Cancer|Melanoma|Colo-rectal Cancer (dMMR/MSI-H CRC)|Hepatocellular Carcinoma|Ulcerative Colitis|Esophageal Cancer|Squamous Cell Carcinoma|Gastric/GEJ|Cervical Cancer|Gastro-Esophageal Adenocarcinoma|Esophageal Adenocarcinoma |
| Interventions | DRUG: nivolumab|DRUG: pembrolizumab |
Participant Information
| Sponsor | Diwakar Davar |
|---|---|
| City | Pittsburgh |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-11-04 |
|---|---|
| Primary Completion Date | 2030-11-30 |
| Completion Date | 2030-11-30 |